Korea Joongang Daily on MSN3h
Samsung Bioepis's' Opuviz gets EC approvalOpuviz, which references Regeneron Pharmacueticals’ vision loss inhibitor Eylea, treats wet age-related macular degeneration, ...
(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...
A breakthrough drug, proven to substantially slow the progression of the ... it deserves credit for being flexible enough to ...
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN18h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...
HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback